3210 Merryfield Row
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics is an industry leader in the application of RNA technologies for the treatment of disease and improved quality of life. The company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. Backed by a management team with extensive experience in the discovery and development of RNA medicines, Arcturus is on the forefront of research and development of RNA delivery technologies.
44 articles with Arcturus Therapeutics
San Diego-based Arcturus Therapeutics announced it was reassuming 100 percent of its global rights for ARCT-810, a messenger RNA (mRNA) drug to treat OTC Deficiency. The drug previously had a 50/50 collaboration between Arcturus and Tubingen, Germany-based CureVac AG.
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
The 2018 BIO International Convention will be officially running from June 4 through June 7 and is celebrating 25 years of innovation.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
Shares of Arcturus Therapeutics are up nearly 10 percent this morning after the company announced it reached a settlement with its former chief executive officer and replaced four members of its board of directors with four new ones.
As part of the amended 13D filing, Mr. Payne has proposed to nominate four director candidates and requested to convene an extraordinary general meeting.
Concurrently, Dr. Pad Chivukula is stepping down as Chief Scientific Officer and Chief Operating Officer and will serve as a Scientific Advisor to the Company.
Joseph E. Payne was shown the door as CEO of Arcturus last week - a move that Payne is not taking lightly.
The company issued a response to the filing issued by the ousted CEO.
Shares of Arcturusare down more than 8 percent in morning trading after the company announced it abruptly terminated Joseph E. Payne as president and CEO.
Arcturus is currently not aware of any other matters that will come before the meeting.
Arcturus Therapeutics Announces Expansion of Collaboration With Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH) and Other GI Disorders
Under the deal, Takeda and Arcturus will advance their efforts to develop RNA-based therapeutics for the treatment of NASH and other gastrointestinal related disorders using Arcturus’s wholly-owned LUNAR lipid-mediated delivery systems .and UNA Oligomer chemistry.
CureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA Therapeutics
Under the agreement, the companies will collaborate to develop up to four molecular therapy products for rare diseases using Curevac’s optimized natural mRNA sequence (RNAoptimizer) and Arcturus’s lipid-mediated nucleic acid delivery system (LUNAR).
Arcturus Therapeutics Announces Completion of Merger With Alcobra and Commences Trading on the Nasdaq Global Market
The combined company has net cash of approximately $50.1 million, following the merger.
Arcturus Therapeutics to Host Key Opinion Leader Call on Advances in Delivery of Nucleic Acid Medicines on Tuesday, November 7
One of the featured speakers on the webcast will be Pad Chivukula, Ph.D., Arcturus’s CSO and COO.
Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to Develop Next-Generation Vaccines and Therapeutics
The collaboration will bring together Arcturus's LUNAR lipid-mediated delivery platform with Synthetic Genomics' RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics.
Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it plans to present at three conferences in November 2017.
The presentations feature multiple Arbutus pipeline programs that highlight the potential of its product candidates and the breadth of its portfolio being advanced to improve current cure rates in chronic HBV.
Shares of Arcturus are up nearly 15 percent in Thursday morning trading after the company inked a collaboration agreement with Janssen Pharma to develop a hepatitis B drug program.